Alterity Therapeutics announced that it has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research to continue its study of ATH434, a small molecule that targets alpha-synuclein, in Parkinson’s disease (PD).
Alterity is already set to begin a Phase 2 trial of ATH434 in multiple system atrophy (MSA) later this year. MSA is a rare neurological disorder with no available treatments for which ATH434 has been granted an Orphan Drug designation.
This new grant will allow Alterity to study ATH434 in a primate model to help determine optimal dosing for future studies in PD. Although there are treatments available for PD, they target the symptoms of the disease rather than the cause. ATH434 was shown in animal models to reduce the misfolding and aggregation of alpha-synuclein, a protein implicated in the cause of MSA and PD, by redistributing iron in the brain.